12:00 AM
 | 
Nov 08, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Thalomid thalidomide: Phase II data; marketed to treat erythema nodosum leprosum in leprosy

University College London researchers presented data from 66 advanced cancer patients given 100 mg Thalomid per day until disease progression or unacceptable toxicity occurred. Partial responses were seen in 3 of 18 renal cancer patients....

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >